RBC Capital Remains a Buy on BioCryst (BCRX)


In a report released today, Brian Abrahams from RBC Capital reiterated a Buy rating on BioCryst (NASDAQ: BCRX), with a price target of $9. The company’s shares opened today at $6.06.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.3% and a 55.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Alder Biopharmaceuticals, and Intra-Cellular Therapies.

BioCryst has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.69 and a one-year low of $3.95. Currently, BioCryst has an average volume of 805.7K.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCRX in relation to earlier this year. Most recently, in May 2018, Jon Stonehouse, the President & CEO of BCRX bought 70,427 shares for a total of $100,006.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts